Today: 1 March 2026
Subscribe
Browse Category

NYSE:PFE 10 November 2025 - 23 November 2025

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer closed Friday at $25.04, up 2.6%, with trading volume above 72 million shares. The company completed a $6 billion bond offering late Friday, spanning maturities from 2027 to 2065. Pfizer’s stock is down about 12% over the past year, despite a recent FDA cancer-drug approval and a multi-billion-dollar obesity drug deal. Dividend yield stands near 6.9%.
23 November 2025
···
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer shares closed up just over 3% at $25.18 on Friday after positive Phase 3 mRNA flu vaccine results, then fell to $24.36 in after-hours trading. The company also completed a $6 billion bond sale to help fund its $10 billion Metsera obesity-drug deal. Pfizer stock remains down about 8% for the year, trailing large-cap pharma peers.
21 November 2025
···
Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its $10 billion acquisition of Metsera, paying $65.60 per share plus a contingent value right of up to $20.65 per share. Metsera shares stopped trading on Nasdaq after November 13. On November 21, Pfizer raised $6 billion through a seven-tranche bond sale to help fund the deal. Metsera is now a Pfizer subsidiary.
21 November 2025
···
Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer shares fell 1.7% to about $24.45 on November 20, 2025, with over 44 million shares traded. The stock’s near-7% dividend yield drew attention, but investors weighed legal concerns, new R&D developments, and uncertainty over post-COVID growth. Pfizer’s quarterly EPS dropped 20% year-over-year to $0.62, with a dividend payout ratio near 70%. Management has not indicated plans to cut the dividend.
20 November 2025
···
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer and Tris Pharma agreed to pay $41.5 million to settle Texas claims over adulterated ADHD drug Quillivant XR. Pfizer also announced a research deal with Nona Biosciences for antibody discovery. At the Jefferies Healthcare Conference, management reaffirmed $7.7 billion in cost cuts and a push into obesity drugs. PFE traded near $25.37 early Wednesday, slightly down from the prior close.
19 November 2025
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····
Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer launched Rimegepant ODT, a migraine tablet, in India, targeting a $200 million market. Shares traded near $25.28, down 55% from late 2022, with a dividend yield around 7%. Analysts maintain a “Hold” rating and see limited short-term movement. The new product addresses migraine in adults unresponsive to standard treatments.
17 November 2025
··
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer completed its $10 billion acquisition of Metsera on November 13, 2025, making Metsera a wholly owned subsidiary and delisting its shares from Nasdaq. Metsera stock last traded at about $70.50 per share before removal. S&P and FTSE Russell are dropping MTSR from their indices. Antitrust scholars are citing Novo Nordisk’s failed bid as a case study in attempted monopolization.
17 November 2025
···
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer shares rose 1.4% to $25.87 Thursday after the company moved to sell its remaining 4.55 million BioNTech ADRs, potentially raising over $500 million. The stock traded between $25.26 and $25.95, with a market cap near $147 billion and a forward dividend yield of about 6.6–7%. BioNTech shares fell on the news. Investors also weighed Pfizer’s recent $10 billion Metsera deal.
13 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Pfizer shares rose 1.7% to $25.94 Wednesday afternoon, trading in a narrow range ahead of next week’s CFO webcast at the Jefferies London Healthcare Conference. Investors are watching for updates on Pfizer’s $10 billion Metsera obesity-drug deal, with a shareholder vote set for November 13. Pfizer recently raised its 2025 EPS outlook and declared a $0.43 Q4 dividend. Market sentiment improved after positive media commentary.
12 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Pfizer will acquire Metsera for up to $10 billion, offering $65.60 per share in cash plus contingent value rights, with a shareholder vote set for Nov. 13. Metsera’s board favored Pfizer over Novo Nordisk after FTC antitrust concerns tipped the balance. Pfizer shares rose about 4–5% to $25.50 following the news. The company also announced seven new trials for its PD‑1×VEGF bispecific antibody, including a phase 3 lung cancer study.
11 November 2025
···
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera shares fell about 15% Monday after the company accepted Pfizer’s revised takeover offer, ending a bidding war with Novo Nordisk. Pfizer will pay $65.60 per share in cash plus up to $20.65 in contingent value rights. Novo withdrew its bid over the weekend. Metsera cited U.S. FTC antitrust concerns with Novo’s proposal.
10 November 2025
····
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

U.S. stock futures rose Monday as Senate action fueled hopes for an end to the government shutdown, with Nvidia up 3% premarket. Pfizer won the $10 billion Metsera bid, sending Novo Nordisk shares higher in Copenhagen. Rumble agreed to buy Germany’s Northern Data in an all-stock deal, gaining access to 22,400 Nvidia GPUs. Tyson Foods raised its FY2026 revenue outlook as chicken sales offset beef weakness.
10 November 2025
····
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Pfizer will acquire obesity drug developer Metsera in a deal worth up to $10 billion, with a shareholder vote set for Nov. 13. Novo Nordisk shares rose after it exited the bidding. Norway’s $1.5 trillion sovereign wealth fund said it will abstain from voting on Novo’s new board at a meeting Nov. 14. Novo also signed a deal to distribute its semaglutide weight-loss shot in India under the brand Poviztra.
10 November 2025
··
Tariffs Fail to Derail European Stock Rally as Markets Bounce Back

GOOGL, NVDA, PFE, NIO, JOBY: 5 Fast‑Profit Catalysts to Watch Today (Nov. 10, 2025)

Nvidia CEO Jensen Huang said demand for Blackwell AI chips is “very strong” and confirmed no active talks to sell them in China. Pfizer’s amended deal with Metsera gained board support ahead of a Nov. 13 vote. Nio remains confident about Q4 profitability despite weak China car sales. Joby Aviation joined a Tokyo eVTOL project set for 2026 launches. Alphabet led a tech rebound after posting a record quarter.
10 November 2025
·····
1 … 5 6 7 8 9
Go toTop